Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 11/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23943397 | 0.93 | MEN1 (0.40) | GAANPC1RAB9AHPGDCASP1 | |
| SCHEMBL23943398 | 0.93 | MEN1 (0.40) | GAANPC1RAB9AHPGDCASP1 | |
| SCHEMBL23943671 | 0.89 | CASP1 (0.41) | GAANPC1RAB9ACASP1SMN1; SMN2 | |
| SCHEMBL22854052 | 0.87 | GAA (0.45) | GAANPC1RAB9ASPHK1SMN1; SMN2 | |
| SCHEMBL22854024 | 0.87 | GAA (0.45) | GAANPC1RAB9ASPHK1SMN1; SMN2 | |
| SCHEMBL23191620 | 0.83 | CASP1 (0.38) | GAAHPGDCASP1SMN1; SMN2MEN1 | |
| SCHEMBL23191619 | 0.83 | CASP1 (0.38) | GAAHPGDCASP1SMN1; SMN2MEN1 | |
| SCHEMBL24496736 | 0.83 | CASP1 (0.44) | GAANPC1RAB9AHPGDCASP1 | |
| SCHEMBL22854050 | 0.83 | CASP1 (0.44) | GAANPC1RAB9AHPGDCASP1 | |
| SCHEMBL24496722 | 0.82 | KMT2A (0.46) | GAANPC1RAB9AHPGDCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022596-A1 | NEOANTIGEN-ELICITING ANTIBODY DRUG CONJUGATES FOR THE IMMUNOTHERAPY OF CANCER | HURT CLARENCE (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022596-A1 | NEOANTIGEN-ELICITING ANTIBODY DRUG CONJUGATES FOR THE IMMUNOTHERAPY OF CANCER | TP53, KLK3, HLA-A | GAA 1006/4885NPC1 2566/4885RAB9A 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.